7MM hidradenitis suppurativa market to quadruple by 2034 | Healthcare Asia Magazine
Photo from Envato

7MM hidradenitis suppurativa market to quadruple by 2034

Thanks to the approval and uptake of next-generation biologics.

The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM), valued $1.84b in 2024, is expected to reach $7.83b in 2034, at a compound annual growth rate of 15.6%, said GlobalData.

The sector’s expansion is attributed to the approval and uptake of next-generation biologics and small molecules with novel mechanisms of action.

The US will lead market growth, accounting for over 70% of sales in 2024, due to a larger diagnosed population, wider biologic access, and premium pricing.

However, HS care is hindered by diagnostic delays averaging up to 10 years, leading to irreversible tissue damage, according to Asiyah Nawab, Healthcare Analyst at GlobalData.

“Furthermore, most biologic treatments are indicated for moderate-to-severe disease, leaving early-stage (Hurley Stage I) patients without effective interventions,” Nawab added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!